VERALOX THERAPEUTICS INC.

Profile

Company Names

VERALOX THERAPEUTICS INC.

Addresses

4539 METROPOLITAN COURT, FREDERICK, MD 21704

Phone Numbers

(301) 360-3502

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2018

State Incorporated:

DELAWARE

Total Amount Raised:

$39,911,021.00

Number of Funding Rounds:

3
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
3
2023-06-01 
$24,013,521.00 
$24,999,971.00 
$986,450.00 
Equity 
2
2021-06-10 
$14,437,500.00 
$22,750,000.00 
$8,312,500.00 
Equity 
1
2019-05-10 
$1,460,000.00 
$4,000,000.00 
$2,540,000.00 
Debt 
People
First Name
Middle Name
Last Name
Titles
Related Companies
JONATHAN 
 
BEHR 
DIRECTOR
IMMUNOMOLECULAR THERAPEUTICS, INC.   |  VERALOX THERAPEUTICS INC.   |  NITROME BIOSCIENCES, INC   |  QURALIS CORP   |  ENDLYZ THERAPEUTICS, INC.   |  DEMENTIA DISCOVERY FUND 2 LP   |  VIOLET THERAPEUTICS, INC.
MATTHEW 
 
BOXER 
EXECUTIVE OFFICER, DIRECTOR
VERALOX THERAPEUTICS INC.
KATIE 
 
ELLIAS 
DIRECTOR
I2O THERAPEUTICS, INC.   |  VERALOX THERAPEUTICS INC.   |  SAB BIOTHERAPEUTICS, INC.
CHRISTOPHER 
 
GAGLIARDI 
DIRECTOR
I2O THERAPEUTICS, INC.   |  VERALOX THERAPEUTICS INC.
MEGAN 
 
KRENCH 
DIRECTOR
VERALOX THERAPEUTICS INC.   |  MEMENTO MEDICINES, INC.
DAVID 
 
MALONEY 
EXECUTIVE OFFICER, DIRECTOR
SCSG EA ACQUISITION COMPANY, INC.   |  EQUITY SOLAR, INC.   |  VERALOX THERAPEUTICS INC.   |  NEROSHIELD, INC.
ALEX 
 
MARTIN 
DIRECTOR
REALM THERAPEUTICS PLC   |  VERALOX THERAPEUTICS INC.   |  FIRST CHAMPION CAPITAL CORP
JONATHAN 
 
MOW 
EXECUTIVE OFFICER, DIRECTOR
PHASEBIO PHARMACEUTICALS INC   |  VERALOX THERAPEUTICS INC.   |  TREFOIL THERAPEUTICS, INC.
BENJAMIN 
 
SCRUGGS 
DIRECTOR
IMMVENTION THERAPEUTIX, INC.   |  VERALOX THERAPEUTICS INC.   |  ALTIS BIOSYSTEMS, INC.
JAMIE 
 
STIFF 
DIRECTOR
VERALOX THERAPEUTICS INC.
JEFFREY 
W. 
STROVEL 
EXECUTIVE OFFICER, DIRECTOR
VERALOX THERAPEUTICS INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2023-06-21
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2023-06-01 
2021-07-07
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2021-06-10 
2019-05-22
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2019-05-10 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#